Influence of Tumor Burden on Treatment Strategies and Clinical Outcomes in LA/mUC Patients Receiving Avelumab First-Line Maintenance: Insights from Real-World Data

In this MEDtalk interview, Dr. Helen Moon, a medical oncologist at Kaiser Permanente Riverside Medical Center, California, USA, discusses the influence of tumor burden on treatment strategies and clinical outcomes for patients with locally advanced or metastatic bladder cancer receiving avelumab as first-line maintenance therapy after platinum-based chemotherapy, based on real-world data that mirrors the JAVELIN Bladder 100 trial.